| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02700763 | Melanoma | Other: [18F]dabrafenib molecular imaging | University Medical Center Groningen | Phase 1 | 2016-10-01 | 2016-09-13 |
| NCT01972347 | Melanoma | Drug: Dabrafenib|Drug: Trametinib | Melanoma Institute Australia | Phase 2 | 2014-10-01 | 2017-03-21 |
| NCT01682213 | Melanoma | Drug: Dabrafenib | Memorial Sloan Kettering Cancer Center|National Comprehensive Cancer Network|Novartis | Phase 2 | 2012-09-01 | 2016-06-07 |
| NCT02052193 | Metastatic Melanoma (Carrying BRAF V600 Mutation) | Drug: Dabrafenib|Drug: Vemurafenib | University Hospital Tuebingen | Phase 2 | 2014-01-01 | 2015-07-17 |
| NCT02231775 | Melanoma | Drug: Dabrafenib|Drug: Trametinib|Procedure: Surgery | M.D. Anderson Cancer Center|Novartis Pharmaceuticals | Phase 2 | 2014-10-01 | 2017-02-10 |
| NCT01726738 | Stage III Melanoma|Stage IV Melanoma|Unresectable Melanoma|BRAF Mutant Melanoma | Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib | UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline | Phase 2 | 2012-10-01 | 2017-03-02 |
| NCT01721603 | BRAFV600E Melanoma Patients | Drug: Dabrafenib|Procedure: Gamma Knife Radiosurgery | University of California, San Francisco|GlaxoSmithKline | Phase 2 | 2013-04-01 | 2016-10-28 |
| NCT02367859 | Ameloblastoma|BRAF Gene Mutation | Drug: Dabrafenib|Other: Laboratory Biomarker Analysis | Stanford University|National Cancer Institute (NCI) | Phase 2 | 2017-04-01 | 2017-03-01 |
| NCT02974803 | Melanoma|Brain Metastases | Drug: Dabrafenib|Drug: Trametinib | Canadian Cancer Trials Group|Novartis | Phase 2 | 2016-11-01 | 2017-03-08 |
| NCT02447939 | Melanoma | Drug: Dabrafenib|Drug: Trametinib | GlaxoSmithKline | Phase 1 | 2017-05-01 | 2017-01-25 |
| NCT01947023 | BRAF V600E Mutation Present|BRAF V600K Mutation Present|Metastatic Malignant Neoplasm in the Thyroid Gland|Recurrent Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma | Drug: Dabrafenib|Other: Laboratory Biomarker Analysis|Drug: Lapatinib Ditosylate|Other: Pharmacological Study | National Cancer Institute (NCI) | Phase 1 | 2013-08-01 | 2016-12-21 |
| NCT01907802 | BRAF Gene Mutation|Hepatic Complication|Renal Failure|Solid Neoplasm | Drug: Dabrafenib|Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Other: Pharmacological Study | National Cancer Institute (NCI)|Glaxosmithkline Biologicals S.A. | Phase 1 | 2013-08-01 | 2017-01-31 |
| NCT01978236 | Melanoma and Brain Metastases | Drug: Dabrafenib 150 mg|Drug: Trametinib 2.0 mg | GlaxoSmithKline | Phase 2 | 2014-04-01 | 2016-12-02 |
| NCT02684058 | Anaplastic Astrocytoma|Glioblastoma|Giant Cell Glioblastoma|Gliosarcoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Anaplastic Ependymoma|Choroid Plexus Carcinoma|Anaplastic Ganglioglioma|Pineal Parenchymal Tumor|Pineoblastoma|Medulloblastoma|PNET|Rhabdoid Tumor|Perineurioma|MPNST|Malignant Meningloma|Anaplastic Hemangiopericytoma | Drug: dabrafenib | Novartis Pharmaceuticals|Novartis | Phase 2 | 2017-07-17 | 2017-02-13 |
| NCT02672358 | Non-Small-Cell Lung Cancer | Drug: Dabrafenib|Drug: Trametinib | Novartis Pharmaceuticals|Novartis | Phase 2 | 2017-10-01 | 2017-01-03 |
| NCT02296996 | Malignant Melanoma | Drug: Dabrafenib + Trametinib | Universitair Ziekenhuis Brussel | Phase 2 | 2014-10-01 | 2016-09-08 |
| NCT02034110 | Cancer | Drug: Dabrafenib|Drug: Trametinib | GlaxoSmithKline | Phase 2 | 2014-03-01 | 2017-02-23 |
| NCT02200562 | Stage III or IV Melanoma | Drug: ipilimumab and dabrafenib | University of Utah | Phase 1 | 2014-12-01 | 2017-02-27 |
| NCT01767454 | Solid Tumours | Drug: Dabrafenib|Drug: Trametinib|Drug: Ipilimumab | GlaxoSmithKline | Phase 1 | 2013-02-01 | 2017-01-23 |
| NCT01677741 | Neoplasms, Brain | Drug: Dabrafenib | GlaxoSmithKline | Phase 1 | 2013-02-01 | 2017-03-04 |
| NCT01584648 | Melanoma | Drug: dabrafenib|Drug: dabrafenib plus trametinib placebo|Drug: Trametinib | GlaxoSmithKline | Phase 3 | 2012-05-01 | 2017-01-10 |
| NCT02083354 | Cancer | Drug: Dabrafenib|Drug: Trametinib | GlaxoSmithKline | Phase 2 | 2014-03-01 | 2017-03-23 |
